Phaseline

Companies › Omeros

Omeros: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 3 Phase 2; Hematology, Genitourinary; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
OMS906–Phase 2C3 Glomerulopathy; Paroxysmal Nocturnal HemoglobinuriaDec 2026
narsoplimab
Mannan-binding lectin serine protease 2 inhibitor
MASP2Phase 2Thrombotic Microangiopathies–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05855083narsoplimabPhase 2Thrombotic MicroangiopathiesHematologyDec 2025
NCT06209736OMS906Phase 2C3 GlomerulopathyGenitourinaryApr 2026
NCT06298955OMS906Phase 2Paroxysmal Nocturnal HemoglobinuriaHematologyDec 2026

From the company's SEC filings

Cash and short-term investments of $132m on 2026-06-30; operating cash outflow about $21m a year; runway about 75 months at that burn, to Oct 2032; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Complete response letters from FDA

Agreements filed with the SEC (item 1.01), last two years

Targets

MASP2 (1)

Companies with the same targets

–

Companies built like this

Climb Bio Shanghai RAAS Blood Products S-INFINITY Pharmaceuticals Prothya Biosolutions Imara

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.